Model-guided development of pharmacokinetic/pharmacodynamic cut-offs and evaluation of sitafloxacin dosing regimens against target pathogens.

ABSTRACT:

Introduction

The establishment of clinical breakpoints for antimicrobial drug is crucial for guiding appropriate therapeutic interventions. This study aims to identify the pharmacokinetic/pharmacodynamic (PK/PD) cut-offs for using sitafloxacin against target pathogens to support clinical breakpoint establishment for antimicrobial drug sensitivity testing.

Methods

A population PK (PopPK) model was built (342 subjects) to calculate the dosing-regimen-dependent (50 mg q12 h, 100 mg q24 h and 100 mg q12 h) PK parameters of sitafloxacin-infected patients, which were combined with in vitro PD data and PK/PD target data. The probabilities of attainment (PTAs) and cumulative fraction of response (CFR) values for different sitafloxacin dosing regimens against Streptococcus

SUBMITTER: Wu H 

PROVIDER: S-EPMC11868765 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature